NCT00569738

Brief Summary

Imaging of neuroendocrine tumors (NETs) relies on conventional morphological methods and on somatostatin receptor scintigraphy (SRS). SRS is effective for carcinoid tumors, and for most pancreatic islet-cell tumors, but may fail to detect some tumors. Furthermore, this technique may require repeated imaging over 24-48 hours. Introduction of newer somatostatin analogs such as DOTANOC improves lesion detection. In addition, labeling with Ga68 and use of PET/CT improves the pharmacokinetics of the tracer resulting in better tumor visualization, and an easier procedure with imaging over only 1-2 hours. In this study, we propose to use Ga68-DOTANOC PET for imaging of various NETs, comparing the imaging data to those of anatomical and other functional modalities, and to histopathology, when available.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 6, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 7, 2007

Completed
12 months until next milestone

Study Start

First participant enrolled

December 1, 2008

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

February 17, 2009

Status Verified

February 1, 2009

First QC Date

December 6, 2007

Last Update Submit

February 16, 2009

Conditions

Neuroendocrine Tumor

Keywords

neuroendocrine tumorsomatostatin analogGallium 68PET

Study Arms (1)

A

patients with neuroendocrine tumors

Procedure: PET scan with Ga68-DOTANOC

Interventions

PET scan with Ga68-DOTANOCPROCEDURE

Imaging: PET scan with Ga68-DOTANOC

A

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

neuroendocrine tumor clinic

You may qualify if:

  • neuroendocrine tumor
  • patients who are able to lie in scanner for up to 50 minutes

You may not qualify if:

  • under age 18
  • pregnant or lactating women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Nuclear Medicine, Hadassah Medical Center

Jerusalem, 91120, Israel

RECRUITING

MeSH Terms

Conditions

Neuroendocrine Tumors

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Yodphat Krausz, MD

    Hadassah Medical Organization

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yodphat Krausz, MD

CONTACT

0097226776705yodphat@hadassah.org.il

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 6, 2007

First Posted

December 7, 2007

Study Start

December 1, 2008

Study Completion

December 1, 2010

Last Updated

February 17, 2009

Record last verified: 2009-02

Locations

IL(1)